



Friday, October 1, 2021

11:00am – 5:15pm EDT

11:00am-11:05am		
Welcome and Program Introduction		
Conference Co-Chairs: Carey Anders, Duke Cancer Institute and Gelareh Zadeh, University Health Network, Toronto Western Hospital/University of Toronto		
SESSION 1: Local Therapies, Innovations and Adoption/Implementation		
Moderators: Gelareh Zadeh, University Health Network, Toronto Western Hospital/University of Toronto and Michael Vogelbaum, Moffitt Cancer		
11:05am - 11:45am	<p>Lessons Learned from Positive and Negative Trials in Glioblastoma and Brain Metastasis</p> <p>One key positive trial and one negative study will be discussed to provide an overview and analysis of trial design, outcome evaluated, and lessons learned as new local therapy strategies are evaluated in future study designs.</p> <p>Glioblastoma (10 minutes each) Positive – TTFIELDS: Roger Stupp Negative -- RTOG 1205: Christina Tsien</p> <p>Brain Metastasis (10 minutes each) Positive -- HA Strategies: Vinai Gondi Negative -- RTOG 1119: In Ah Kim</p>	<p>Roger Stupp, Robert H. Lurie Comprehensive Cancer Center of Northwestern University Christina Tsien, Johns Hopkins</p> <p>Vinai Gondi, Northwestern Medicine Cancer Center Warrenville and Proton Center In Ah Kim, Seoul National University</p>
11:45am - 11:50am	Q & A	
11:50am - 12:00pm	Abstract IMM0-02: Phase I/II Study of Laser Interstitial Thermotherapy (LITT) Combined with Checkpoint Inhibitor for Recurrent Glioblastoma (rGBM): Preliminary Results	Andrew Sloan, University Hospitals-Seidman Cancer Center
12:00pm - 12:10pm	Abstract SYST-05: Phase 2 Study of VAL-083 and Radiotherapy in Newly Diagnosed MGMT-unmethylated GBM	Zhong-ping Chen, Sun Yat-sen University Cancer Center, China
12:10pm - 12:20pm	Abstract SYST-07: Pilot Study Utilizing the HDAC Inhibitor Belinostat with Chemoradiation for Newly-diagnosed Glioblastoma	Hui-Kuo Shu, Emory University
12:20pm - 12:25pm	Q & A	
12:25pm - 12:45pm	<p>Panel Discussion</p> <p>Opportunities for Evaluating Local Therapies in the Management of CNS Malignancies</p>	<p>Moderator: Michael Vogelbaum, Moffitt Cancer Center</p> <p>Panelists:</p>

		Roger Stupp, Robert H. Lurie Comprehensive Cancer Center of Northwestern University Christina Tsien, Johns Hopkins Vinai Gondj, Northwestern University In Ah Kim, Seoul National University Rupesh Kotecha, Miami Cancer Institute Alireza Mansouri, Penn State Cancer Institute Minesh Mehta, Miami Cancer Institute Gelareh Zadeh, University Health Network, Toronto Western Hospital/University of Toronto
12:45pm - 12:55pm	BREAK	
SESSION 2: Systemic Therapeutics: Lessons Learned from Past Experience Moderators: Carey Anders, Duke Cancer Institute and Howard Colman, Huntsman Cancer Institute, University of Utah		
12:55pm - 1:10pm	Changing Landscape for NSCLC BrMets: Beyond EGFR and ALK...	Sarah Goldberg, Yale School of Medicine
1:10pm - 1:25pm	Targeted Therapy for GBM: How to Prioritize Targets and When is it Time to Move on?	Howard Colman, Huntsman Cancer Institute, University of Utah
1:25pm - 1:30pm	Q & A	
1:30pm - 1:40pm	Abstract SYST-08: A phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients with an Unmethylated MGMT Gene Promoter (A01-M121-11A, McG1132)	Mame Daro Faye, McGill University Health Centre
1:40pm - 1:50pm	Abstract SYST-04: TRAM-01: A Phase 2 Study of Trametinib for Patients with Pediatric Glioma with Activation of the MAPK/ERK Pathway.	Sébastien Perreault, CHU Sainte-Justine, Montreal
1:50pm - 1:55pm	Q & A	
1:55pm - 2:20pm	Panel Discussion Use of Next Generation Sequencing in the Care of Patients with Primary and Metastatic Brain Tumors	Panel Moderators: Nancy Lin, Dana Farber Cancer Institute Solmaz Sahebjam Panel: Carey Anders, Duke Cancer Institute Sarah Goldberg, Yale School of Medicine Howard Colman, Huntsman Cancer Institute, University of Utah Martin van den Bent, Erasmus University, Netherlands Sara Hurvitz, University of California, Los Angeles; Jonsson Comprehensive Cancer Center Michael Weller, University Hospital, Zurich
2:20pm - 2:30pm	BREAK	

SESSION 3: Immunotherapy: Hype and Hope Moderators: Priscilla Brastianos, Massachusetts General Hospital/Harvard Medical School and Michael Platten, University Medical Center Mannheim		
2:30pm - 2:45pm	CAR T Cells for the Treatment of Glioblastoma	Christine Brown, City of Hope
2:45pm - 3:00pm	Oncolytic Viruses in Primary Brain Tumors	Maciej Lesniak, Northwestern University
3:00pm - 3:15pm	Checkpoint Blockade in Brain Metastases -- Status Update and Future Outlook	Hussein Tawbi, University of Texas, MD Anderson Cancer Center
3:15pm - 3:20pm	Q & A	
3:20pm - 3:30pm	Abstract IMMU-01: TEM-GBM: An Open-label, Phase I/IIa Dose-escalation Study Evaluating the Safety and Efficacy of Genetically Modified Tie-2 Expressing Monocytes to Deliver IFN- α within Glioblastoma Tumor Microenvironment	Gaetano Finocchiaro, Ospedale San Raffaele, Milan
3:30pm - 3:40pm	Abstract IMMU-06: Targeting IDH1 Mutant Grade II Recurrent Gliomas Using a Peptide Vaccination Strategy	Aditya Mohan, Duke University
3:40pm - 3:50pm	Abstract SYST-03: A Phase I/II Study to Evaluate Safety and Preliminary Activity of the Tumor-targeting Antibody-cytokine Fusion Protein L19TNF in Patients with Glioblastoma at First Relapse	Tobias Weiss, University Hospital and University of Zurich
3:50pm - 3:55pm	Q & A	
3:55pm - 4:15pm	Panel Discussion Immunotherapy for Primary and Metastatic Brain Tumors: Hope or Hype	Moderators: Priscilla Brastianos, Massachusetts General Hospital/Harvard Medical School Peter Fecci, Duke University Panelists: Christine Brown, City of Hope Maciej Lesniak, Northwestern University Hussein Tawbi, University of Texas, MD Anderson Cancer Center Evanthia Galanis, Mayo Clinic Mustafa Khasraw, Duke University Michael Platten, University Medical Center Mannheim Jana Portnow, City of Hope
4:15pm - 5:15pm	Town Hall: Transforming Patients from Subject to Partners Chairs/Moderators: Mark Gilbert, National Institutes of Health and Nancy Lin, Dana Farber Cancer Institute Panel: David Arons, National Brain Tumor Society; Ralph DeVitto, American Brain Tumor Association; Lianne Kraemer, Patient and Advocate; J.C. Richardson and his wife Luann, Patient and Advocate; Kathleen Wall, Research Nurse at National Institutes of Health Evanthia Galanis, Mayo Clinic; Minesh Mehta, Miami Cancer Institute; Terri Armstrong, National Cancer Institute; Tatiana Prowell, US Food & Drug Administration	
5:15pm	Closing Remarks: Nancy Lin	

Saturday, October 2, 2021

11:00am – 4:25pm EDT

11:00am-11:05am Welcome Conference Co-Chairs: Carey Anders, Duke University and Gelareh Zadeh, University Health Network, Toronto Western Hospital/University of Toronto		
11:05am-11:25am Keynote: Regulatory Considerations for the Treatment of CNS Tumors: Past, Present and Future Amy Barone, US Food & Drug Administration		
SESSION 1: Neuroimaging Moderators: Mustafa Khasraw, Duke University and Alireza Mansouri, Penn State Cancer Institute		
11:25am - 11:40am	Imaging Endpoint of Subclinical Therapeutic Activity in Early Phase Clinical Trials for Brain Tumors	Benjamin Ellingson, University of California, Los Angeles
11:40am - 11:55am	How to Evaluate Intratumoral Delivery of Investigational Therapies	Michael Vogelbaum, Moffitt Cancer Center
11:55am - 12:05pm	Abstract NEIM-05: [Ga68]DOTATATE PET/MRI-based Radiosurgical Response Assessment in Meningioma	Jana Ivanidze, Weill Cornell Medicine
12:05pm - 12:15pm	Abstract CLRM-07: Increasing Efficiency in Early Phase Multicenter Imaging Biomarker Trials: Emerging Strategies from the GABLE (Glioblastoma Accelerated Biomarker Learning Environment) Trial	Daniel Barboriak, Duke University Medical Center
12:15pm - 12:20pm	Q & A	
12:20pm - 12:30pm	Panel Discussion Advances in Neuroimaging: Integrating into Future Neuro-oncology Trials	Moderators: Mustafa Khasraw, Duke University Alireza Mansouri, Penn State Cancer Institute Panelists: Benjamin Ellingson, University of California, Los Angeles Michael Vogelbaum, Moffitt Cancer Center Jerrold Boxerman, Rhode Island Hospital/Alpert Medical School of Brown University Caroline Chung, University of Texas, MD Anderson Cancer Center Elisabeth de Vries, University Medical Centre Groningen, Netherlands Patrick Wen, Dana Farber Cancer Institute
SESSION 2: Integration of Supportive Care and Survivorship into Clinical Trials Moderators: Susan Chang, University of California, San Francisco and Solmaz Sahebjam		

12:30pm - 12:45pm	Influence of Symptomatic and Supportive Care on Efficacy Endpoints in Clinical Trials: Myth or Reality	Emilie Le Rhun, University Hospital Zurich
12:45pm - 1:00pm	Assessing Clinical Benefit in CNS Tumor Trials Using Patient-Reported Outcomes	Terri Armstrong, National Cancer Institute
1:00pm - 1:15pm	Assessing Clinical Benefit in CNS Clinical Trials -- Neurocognitive Function	Jeffrey Wefel, University of Texas, MD Anderson Cancer Center
1:15pm - 1:30pm	Methodological Considerations When Including COAs into CNS Clinical Trials	Linda Dirven, Leiden University Medical Center, Netherlands
1:30pm - 1:35pm	Q & A	
1:35pm - 1:55pm	Panel Discussion Integration of Supportive Care in Clinical Practice and Research	Moderators: Susan Chang, University of California, San Francisco Solmaz Sahebjam Panelists: Emilie Le Rhun, University Hospital Zurich Terri Armstrong, National Cancer Institute Linda Dirven, Leiden University Medical Center, Netherlands Jeffrey Wefel, University of Texas, MD Anderson Cancer Center
1:55pm - 2:05pm	BREAK	
SESSION 3: Clinical Research Methods in 21st Century Moderator: Mustafa Khasraw, Duke University and Hussein Tawbi, University of Texas MD Anderson Cancer Center		
2:05pm - 2:20pm	Precision Oncology Clinical Trial Designs That Integrate Biomarker Evaluation	Mei-Yin C. Polley, University of Chicago
2:20pm - 2:35pm	Leveraging External Data in Design and Analysis of Clinical Trials in Glioblastoma	Rifaquat Rahman, Dana Farber/Brigham and Women's Cancer Center
2:35pm - 2:50pm	Basket, Umbrella and Platform Trials in Neuro-oncology	Evanthia Galanis, Mayo Clinic
2:50pm - 3:00pm	Q&A	
3:00pm - 3:10pm	Abstract CLRM-12: Hybrid Designs for Using External Controls in Phase 3 Glioblastoma Trials	Daniel Schwartz, University of Chicago
3:10pm - 3:20pm	Abstract CLRM-09: Incorporating External Control Arm in MDNA55 Recurrent Glioblastoma Registration Trial	Ruthanna Davi, Medidata Acorn AI
3:20pm - 3:30pm	Abstract CLRM-01: Machine Learning to Uncover Signatures of Vulnerability in Glioblastoma Umbrella Signature Trial (GUST)	Sen Peng, The Translational Genomics Research Institute
3:30pm - 3:35pm	Q&A	
3:35pm - 3:50pm	Current Drug Development and Trial Designs in Neuro-oncology: Are We Trying Hard Enough?	Steven Piantadosi, Brigham and Women's Hospital

3:50pm - 4:10pm	<p>Panel Discussion Can We Conduct Better Clinical Trials in Neuro-oncology?</p>	<p>Moderators: Mustafa Khasraw, Duke University Hussein Tawbi, University of Texas, MD Anderson Cancer Center</p> <p>Panelists: Mei-Yin C. Polley, University of Chicago Rifaquat Rahman, Dana Farber/Brigham and Women's Cancer Center Evanthia Galanis, Mayo Clinic Steven Piantadosi, Brigham and Women's Hospital John de Groot Susan Geyer, Mayo Clinic Minesh Mehta, Miami Cancer Institute Patrick Wen, Dana Farber Cancer Institute Alexandra Zimmer, National Cancer Institute</p>
4:10pm - 4:20pm	<p>Wrap Up Optimizing and Supporting Clinical Research in Neuro-oncology to Improve Patient Outcomes -- Evanthia Galanis, Mustafa Khasraw, Minesh Mehta</p>	
4:20pm - 4:25pm	<p>Closing Remarks Conference Co-Chairs Elect: Priscilla Brastianos, Massachusetts General Hospital/Harvard Medical School and Mustafa Khasraw, Duke University</p>	